Cognition Therapeutics Presents Results at AD/PD 2025 Showing Impact of Zervimesine (CT1812) on Alzheimer's Disease Processes

Core Insights - Cognition Therapeutics, Inc. presented biomarker results from the Phase 2 SHINE study of zervimesine (CT1812) for mild-to-moderate Alzheimer's disease at the AD/PD 2025 Conference [1] - The study focused on changes in biomarkers, particularly in a subgroup with lower levels of p-Tau217, which is indicative of Alzheimer's pathology [2] Study Findings - Participants receiving zervimesine for six months showed reductions in plasma biomarkers associated with Alzheimer's compared to placebo [3] - Significant reductions were noted in glial fibrillary acidic protein (GFAP) and neurofilament light (NfL), both linked to neuroinflammation and neurodegeneration, respectively [4] - The low-p-Tau217 subgroup exhibited more pronounced reductions in biomarkers, correlating with cognitive improvements observed in this group [5] Presentation Details - The presentation included multiple studies highlighting the positive impact of CT1812 on plasma biomarkers and cognitive outcomes in Alzheimer's patients [5] - Key authors of the studies presented include Mary Hamby, Ph.D., and others, with presentations scheduled at various locations during the conference [5] Company Overview - Cognition Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapeutics for neurodegenerative disorders, with zervimesine as a lead candidate [6] - The company is exploring zervimesine's mechanism of action through its interaction with the sigma-2 receptor, which is distinct from other treatment approaches [6]